Alpha Profiles · Company Profile

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/lixte-biotechnology-holdings-inc

Entity: Public listing published
Primary listing: NASDAQ: LIXT
Verification: Partially verified
Last reviewed: 2026-09-13T04:48:41.158806+00:00

Overview

Alpha's canonical identity and public leadership record for LIXTE BIOTECHNOLOGY HOLDINGS, INC..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

3 public records

Bastiaan van der Baan

Chief Scientific Officer

State: confirmed
Effective: From Mar 31, 2026
Confidence: 94%
Evidence: LIXT 10-K executive officersMar 31, 2026

Geordan Pursglove

President, Chief Executive Officer, and Chairman of the Board of Directors

State: confirmed
Effective: From Mar 31, 2026
Confidence: 94%
Evidence: LIXT 10-K executive officersMar 31, 2026

Peter Stazzone

Chief Financial Officer

State: confirmed
Effective: From Mar 31, 2026
Confidence: 94%
Evidence: LIXT 10-K executive officersMar 31, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 13, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.